In a patient with otherwise low-risk prostate cancer, does presence of a small component of Grade Group 3 disease up-stage to unfavorable intermediate?  

I agree with Dr. @Patel's response and will just add a couple of additional thoughts. There are many things that go into making a decision about whether treatment is necessary, and what type of treatment is performed. In this case, it's important to consider patient factors (i.e. age, co-morbid cond...

While there is some evidence that the total length of Gleason pattern 4 may improve the prediction of adverse pathology over the percentage of pattern 4, I continue to employ the NCCN risk stratification and accompanying treatment algorithm, which classifies such patients as unfavorable intermediate...

To answer the question at face value - Yes, I would treat as per UFIR, meaning no active surveillance. In regard to the other answers, I partially disagree with Dr. @Patel and mostly agree with Dr. @Russo. I am unconvinced that 0815 gives any of us a reason to routinely omit ADT in any patient who ...